Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Crain's New York10h
FiDi-based obesity drug maker sees $1.9B IPO
Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.
Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
The Healthy on MSN12h
6 Foods To Eat on Semaglutides, Listed by a Doctor of Obesity Medicine
A triple-board-certified MD of lifestyle and obesity medicine lists the foods that will optimize your medication's efficacy and minimize unwanted side effects.
‘The Challenge’ Star Aneesa Ferreira Shows Off Impressive Weight Loss
Aneesa Ferreira is getting fit! The Challenge star posted a new before-and-after look at her recent weight loss over the past ...
FierceBiotech16h
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...